Have you been recently diagnosed with glioblastoma?

EX-TEM – A clinical trial to determine if extending temozolomide chemotherapy after radiation improves survival in patients with newly diagnosed glioblastoma

Patients diagnosed with glioblastoma are treated with a combination of chemotherapy and radiation, followed by six months of temozolomide (chemotherapy). However, even with the best treatment, the average survival is around 14 months. Previous research has suggested that an extra six months of temozolomide may improve survival without any impact on quality of life or symptoms related to treatment. However, these studies were small and unable to provide a definitive answer. In some centres, it is standard to use six months of chemotherapy, whilst in others, the standard is 12 months.

The purpose of this study is to determine if an additional six months of temozolomide will improve the survival of patients with glioblastoma. We will also assess whether an additional six months of temozolomide causes more side effects.

Patients who decide to participate in the trial will be randomly assigned to either receive an additional six months of temozolomide chemotherapy or not and continue with their usual care.

Anticipated date that enrolment will close: November 2020

Who can take part

  • People who have been diagnosed with glioblastoma in the last 9 months
  • Aged 18 years and older
  • Completed radiation with temozolomide chemotherapy, followed by six months of post-radiation temozolomide chemotherapy
  • No evidence of progressive disease on brain imaging.
  • Tolerated temozolomide chemotherapy and safe to continue

What is involved for you?

Participants enrolled will undergo routine blood tests prior to the administration of chemotherapy which is part of standard hospital care.

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4

For more information

Quote reference number
2017.350
Megan Dumas
(03) 9345 2747
Maria Edmonds
(03) 9345 2896